Constructive Bio
Synthetic biology / biotech, Cambridge
Synthetic genomics platform engineering cells to make novel peptides and biomolecules. It raised $58m in its Series A in September 2024. It has 2 roles open, 0 of them in the UK.
Backed by Ahren Innovation Capital, OMX Ventures and Paladin Capital Group. Total raised ~$75m.
On the Home Office register of licensed visa sponsors.
- 26 daystypical age of an open role
- 0roles open for more than 60 days
- 3roles taken down since we started tracking
- 0%of roles list a salary
Open roles
2 live todayOpen roles over time
Hiring momentum
Roles per weekAdded (by posting date)Closed (removed from the board)In the news (hover for headline)
Open roles by function
Open roles by team
As the company labels themIn the news
All 14 stories- LeadershipBusiness Wire, 25 Jun 2026Constructive Bio Founder and Chief Scientific Officer, Professor Jason Chin, Named the 2026 Heinrich Wieland Prize Recipient
- OtherBusiness Weekly, 26 May 2026Constructive Bio adds Weissman to world-class board
- ExpansionSynBioBeta, 1 May 2026Constructive Bio's Ola Wlodek on Commercialising the Expanded Genetic Code
- Profiles & interviewsAmadeus Capital Partners, 25 Feb 2026In Focus: Rewriting life’s blueprint with Ola Wlodek of Constructive Bio
- OtherSynBioBeta, 19 Nov 2025From Genome Writing to Novel Polymers: Constructive Bio's and Jason Chin’s Bold Vision for Engineered Biology
- Partnerships & dealsBusiness Weekly, 18 Nov 2025Constructive Bio and RxCelerate partner to develop biologic therapeutic candidates